Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 7/20 | 0.55 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | GJA1 | P17302 | 5/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.45 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805976 | 1.00 | GJB2 (0.55) | GJB2SSTR5SLC6A2GJA1SSTR4 | |
| SCHEMBL5555711 | 0.88 | GJB2 (0.53) | GJB2SSTR5GJA1SSTR4NT5E | |
| SCHEMBL15514243 | 0.88 | GJB2 (0.53) | GJB2SSTR5GJA1SSTR4NT5E | |
| SCHEMBL6805981 | 0.88 | GJB2 (0.53) | GJB2SSTR5GJA1SSTR4NT5E | |
| SCHEMBL15541898 | 0.88 | GJB2 (0.53) | GJB2SSTR5GJA1SSTR4NT5E | |
| SCHEMBL23742931 | 0.88 | NT5E (0.51) | GJB2SSTR5SLC6A2SSTR4NT5E | |
| SCHEMBL7156143 | 0.88 | NT5E (0.51) | GJB2SSTR5SLC6A2SSTR4NT5E | |
| SCHEMBL7639364 | 0.88 | NT5E (0.51) | GJB2SSTR5SLC6A2SSTR4NT5E | |
| SCHEMBL7154719 | 0.88 | NT5E (0.51) | GJB2SSTR5SLC6A2SSTR4NT5E | |
| SCHEMBL25585675 | 0.88 | NT5E (0.51) | GJB2SSTR5SLC6A2SSTR4NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | UNIVERSITY OF MARYLAND, COLLEGE PARK | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218342-A1 | SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF | GAA, MAN2B1, M6PR | GJB2 4371/4885SSTR5 1194/4885SLC6A2 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.